STERIS plc provides infection prevention and other procedural products and services worldwide. The company operates in four segments: Healthcare Products, Healthcare Specialty Services, Life Sciences, and Applied Sterilization Technologies. The Healthcare Products segment offers cleaning chemistries and sterility assurance products; accessories for gastrointestinal (GI) procedures, washers, sterilizers, and other pieces of capital equipment for the operations of a sterile processing department; and equipment used in the operating room, including surgical tables, lights, equipment management services, and connectivity solutions. It also provides capital equipment install, maintain, upgrade, repair, and troubleshoot services. This segment provides its products and services to acute care hospitals, ambulatory surgery centers, and GI clinics. The Healthcare Specialty Services segment provides solutions and managed services, including instrument and endoscope repair and maintenance solutions; and custom process improvement consulting and outsourced sterile processing services to acute care hospitals and other healthcare settings. The Life Sciences segment offers formulated cleaning chemistries, barrier products, sterility assurance products, steam and vaporized hydrogen peroxide sterilizers, and washer disinfectors. The Applied Sterilization Technologies segment provides contract sterilization services using gamma, electron beam, and X-ray technologies, as well as ethylene oxide and hydrogen peroxide; and laboratory testing services. It operates a network of approximately 50 facilities. The company was founded in 1985 and is based in Derby, the United Kingdom.
Industry, Sector and Symbol
Industry Surgical appliances & supplies
Sub-IndustryHealth Care Equipment
SectorMedical
Phone44-13-3238-7100
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$2.62 billion
Profitability
Miscellaneous
Employees12,000
OptionableOptionable
Steris (NYSE:STE) Frequently Asked Questions
What is Steris' stock symbol?
Steris trades on the New York Stock Exchange (NYSE) under the ticker symbol "STE."
How often does Steris pay dividends? What is the dividend yield for Steris?
Steris announced a quarterly dividend on Wednesday, February 6th. Shareholders of record on Wednesday, February 27th will be given a dividend of $0.34 per share on Thursday, March 21st. This represents a $1.36 annualized dividend and a yield of 1.11%. The ex-dividend date of this dividend is Tuesday, February 26th. View Steris' Dividend History.
How were Steris' earnings last quarter?
Steris PLC (NYSE:STE) released its quarterly earnings data on Monday, February, 11th. The medical equipment provider reported $1.26 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.26. The medical equipment provider had revenue of $696.24 million for the quarter, compared to the consensus estimate of $687.90 million. Steris had a net margin of 9.85% and a return on equity of 12.50%. View Steris' Earnings History.
When is Steris' next earnings date?
What guidance has Steris issued on next quarter's earnings?
Steris updated its FY 2019 earnings guidance on Monday, February, 11th. The company provided earnings per share (EPS) guidance of $4.74-4.84 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $4.76. The company issued revenue guidance of $2.751-2.751 billion, compared to the consensus revenue estimate of $2.75 billion.
What price target have analysts set for STE?
4 equities research analysts have issued 1-year price objectives for Steris' shares. Their forecasts range from $132.00 to $157.00. On average, they expect Steris' stock price to reach $139.75 in the next twelve months. This suggests a possible upside of 14.3% from the stock's current price. View Analyst Price Targets for Steris.
What is the consensus analysts' recommendation for Steris?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Steris in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Steris.
What are Wall Street analysts saying about Steris stock?
Here are some recent quotes from research analysts about Steris stock:
- 1. JMP Securities analysts commented, "We reiterate our Market Outperform rating on STERIS and price target of $135 following the release of F3Q19 results. STE announced quarterly results following Monday’s close, and will hold its call at 10 a.m. ET today; we will look for more color on guidance, as well as revenue and earnings drivers at that time. Our $135 price target is based on 23-24x our CY20 EPS estimate of $5.70. Our multiple reflects a slight discount to a group of mid-to-high single-digit growing, mid- cap MedTech peers." (2/14/2019)
- 2. According to Zacks Investment Research, "STERIS exited second-quarter fiscal 2019 on a promising note with earnings and revenues both exceeding the respective Zacks Consensus Estimate. We are impressed with the company’s persistently strong organic growth performance across major segments. The company is currently demonstrating strong top line growth on favorable underlying market trends along with new product and service offerings. Further, growth in free cash flow reserve is indicative of the company’s strong cash balance. The company raising its overall guidance for fiscal 2019 is also indicative of brighter prospects. STERIS has also made certain acquisitions, divestments and organizational changes, which are expected to better align with its operations. Over the past three months, STERIS has been outperforming its industry." (11/16/2018)
- 3. KeyCorp analysts commented, "Our price target of $20/share is based on an equally-weighted composite of: (a) $21.3/share, as a 25x multiple of taxed and diluted $11.7 discounted back to FY18 at 30% (in line with the expected PE multiple and discount rate of an early development-stage biotechnology company); and (b) an NPV of $21.3/ share (discounted cash flow analysis using a 20% discount rate and 2.0% growth rate, in line with the expected discount and growth parameters of an early development-stage biotechnology company)." (8/9/2018)
Has Steris been receiving favorable news coverage?
News articles about STE stock have been trending negative on Sunday, according to InfoTrie. The research firm identifies positive and negative press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Steris earned a news impact score of -2.8 on InfoTrie's scale. They also assigned press coverage about the medical equipment provider a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the immediate future.
Who are some of Steris' key competitors?
Some companies that are related to Steris include Edwards Lifesciences (EW), Zimmer Biomet (ZBH), Align Technology (ALGN), COLOPLAST A/S/ADR (CLPBY), Smith & Nephew (SNN), WILLIAM DEMANT/ADR (WILYY), MSA Safety (MSA), Wright Medical Group (WMGI), Inogen (INGN), Avanos Medical (AVNS), Establishment Labs (ESTA), Sientra (SIEN), RTI Surgical (RTIX), Invacare (IVC) and Lakeland Industries (LAKE).
Who are Steris' key executives?
Steris' management team includes the folowing people:
- Mr. Walter M. Rosebrough Jr., CEO, Pres & Director (Age 65)
- Mr. Michael J. Tokich, Sr. VP & CFO (Age 50)
- Mr. Daniel A. Carestio, Chief Operating Officer (Age 46)
- Mr. John Adam Zangerle, VP, Gen. Counsel & Sec. (Age 52)
- Dr. Adrian Vincent Coward, Sr. VP of Healthcare Specialty Services (Age 49)
Who are Steris' major shareholders?
Steris' stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (10.11%), Oregon Public Employees Retirement Fund (4.23%), WCM Investment Management LLC (2.80%), Massachusetts Financial Services Co. MA (2.29%), Fisher Asset Management LLC (1.67%) and Principal Financial Group Inc. (1.66%). Company insiders that own Steris stock include Cynthia L Feldmann, Daniel A Carestio, Jacqueline B Kosecoff, John Adam Zangerle, Karen L Burton, Kathleen Bardwell, Loyal W Wilson, Michael B Wood, Michael J Tokich, Mohsen Sohi, Richard Martin Steeves, Sudhir K Pahwa, Walter M Rosebrough Jr and Walter M Rosebrough, Jr. View Institutional Ownership Trends for Steris.
Which institutional investors are selling Steris stock?
STE stock was sold by a variety of institutional investors in the last quarter, including Massachusetts Financial Services Co. MA, Bessemer Group Inc., Principal Financial Group Inc., Victory Capital Management Inc., Macquarie Group Ltd., Lord Abbett & CO. LLC, Congress Asset Management Co. MA and Retirement Systems of Alabama. Company insiders that have sold Steris company stock in the last year include Cynthia L Feldmann, Daniel A Carestio, Jacqueline B Kosecoff, John Adam Zangerle, Karen L Burton, Loyal W Wilson, Michael B Wood, Michael J Tokich, Mohsen Sohi, Richard Martin Steeves, Sudhir K Pahwa, Walter M Rosebrough Jr and Walter M Rosebrough, Jr. View Insider Buying and Selling for Steris.
Which institutional investors are buying Steris stock?
STE stock was purchased by a variety of institutional investors in the last quarter, including Oregon Public Employees Retirement Fund, BlackRock Inc., Villere ST Denis J & Co. LLC, Millennium Management LLC, Westfield Capital Management Co. LP, Mackenzie Financial Corp, Canada Pension Plan Investment Board and Acadian Asset Management LLC. View Insider Buying and Selling for Steris.
How do I buy shares of Steris?
Shares of STE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Steris' stock price today?
One share of STE stock can currently be purchased for approximately $122.28.
How big of a company is Steris?
Steris has a market capitalization of $10.34 billion and generates $2.62 billion in revenue each year. The medical equipment provider earns $290.91 million in net income (profit) each year or $4.15 on an earnings per share basis. Steris employs 12,000 workers across the globe.
What is Steris' official website?
How can I contact Steris?
Steris' mailing address is Rutherford House Stephensons Way Chaddesden, Derby X0, DE21 6LY. The medical equipment provider can be reached via phone at 44-13-3238-7100 or via email at [email protected]
MarketBeat Community Rating for Steris (NYSE STE)
MarketBeat's community ratings are surveys of what our community members think about Steris and other stocks. Vote "Outperform" if you believe STE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe STE will underperform the S&P 500 over the long term. You may vote once every thirty days.
